Papadopoulos, K. P.; Owonikoko, T. K.; Johnson, M. L.; Brana, I.; Gil-Martin, M.; Perez, R. P.; Moreno, V.; Salama, A. K.; Calvo, E.; Yee, N. S.; Safran, H.; Gonzalez-Martin, A.; Aljumaily, R.; Mahadevan, D.; Mohan, K. K.; Li, J.; Stankevich, E.; Lowy, I.; Fury, M. G.; Homsi, J. Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. J of Skin 2018, 2, S45.